LTP LTR PHARMA FPO [LTP]
Healthcare · Biotechnology
· website
$0.46
52wk 0.32 – 0.81
Overall
—
Value
—
Growth
—
Health
—
Quality
—
Momentum
—
Dividend
—
Price
About LTR PHARMA FPO [LTP]
LTR Pharma Limited, a clinical-stage pharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia. Its lead product candidate is SPONTAN, an intranasal delivery technology, an oral PDE5 inhibitor and vardenafil HCL for the treatment of ED. The company was incorporated in 2020 and is headquartered in Brisbane, Australia.
Fundamental trends
Financial statements
Loading…
Key metrics
Market cap
$83.62M
P/E (trailing)
—
P/E (forward)
—
EPS (trailing)
-0.05
Dividend yield
—
Payout ratio
0.0%
Beta
2.18
EV / EBITDA
-6.00
Price / Book
3.11
ROE
-29.3%
Operating margin
-8,230.9%
Net margin
0.0%
Total cash
$25.78M
Total debt
$0
Current ratio
57.47
Debt / Equity
—
Free cash flow
$-4.47M
Avg volume
413,412
Latest annual results
(FY ending 30 Jun 2025)
- Revenue$145.78K
- Gross profit$145.78K
- Operating income-$7.47M
- Net income-$5.59M
- Diluted EPS-0.03
- Free cash flow-$4.45M
- Net debt-$31.81M